# Quest Diagnostics (DGX) Stock Analysis: A Healthcare Leader with a 12% Potential Upside

- Link: https://www.directorstalkinterviews.com/quest-diagnostics-dgx-stock-analysis-a-healthcare-leader-with-a-12-potential-upside/4121209582
- Published: 2025-07-28T10:39:37+01:00
- Author: Madison Wilson

Quest Diagnostics Incorporated (NYSE: DGX) stands as a prominent player in the healthcare
sector, specifically within the diagnostics and research industry. With a substantial
market capitalization of $18.85 billion, Quest Diagnostics has established itself
as a key provider of diagnostic testing services both in the United States and internationally.
As the healthcare industry continues to evolve, Quest Diagnostics remains at the
forefront, offering a comprehensive range of services that cater to the needs of
physicians, hospitals, health plans, and patients alike.

The current stock price of Quest Diagnostics sits at $168.55, reflecting a minor
decrease of $3.35 or 0.02%. Investors may find this a compelling entry point, especially
considering the stock’s 52-week range of $142.14 to $182.07. With an average target
price set at $188.81 by analysts, the potential upside of 12.02% offers an enticing
opportunity for those looking to capitalize on the stock’s growth trajectory.

Valuation metrics provide further insights into the stock’s potential. Despite the
absence of a trailing P/E ratio, the forward P/E stands at 16.13, suggesting that
the stock is reasonably priced relative to its earnings expectations. This aligns
with the company’s strong revenue growth of 15.20%, indicating robust business expansion.
The earnings per share (EPS) of 8.34 and a return on equity of 14.26% underscore
the company’s profitability and efficient utilization of shareholder equity.

Quest Diagnostics also offers an attractive dividend yield of 1.90%, with a payout
ratio of 46.11%. This dividend policy not only provides a steady income stream for
investors but also reflects the company’s commitment to returning capital to shareholders
while maintaining sufficient reinvestment in its growth initiatives.

Analyst sentiment towards Quest Diagnostics is predominantly positive, with 9 buy
ratings and 9 hold ratings, and no sell ratings. This balanced view suggests confidence
in the company’s long-term prospects while acknowledging potential short-term market
fluctuations. The target price range of $166.00 to $200.00 indicates room for appreciation,
with the possibility of the stock reaching new highs.

Technical indicators present a mixed picture, with the 50-day moving average of 
$174.45 and the 200-day moving average of $165.26. The stock’s RSI (14) at 69.11
suggests it is approaching overbought territory, which could indicate a consolidation
phase or potential correction. However, the MACD of -1.59 and a signal line of -
1.66 might suggest a cautious approach in the immediate term.

Founded in 1967 and headquartered in Secaucus, New Jersey, Quest Diagnostics continues
to innovate and expand its service offerings. Its diagnostic information services,
delivered under various brands including AmeriPath, Dermpath Diagnostics, and ExamOne,
are critical to the healthcare ecosystem. The company’s extensive network of laboratories
and patient service centers ensures broad accessibility and convenience, further
solidifying its market position.

For investors seeking exposure to the healthcare sector, Quest Diagnostics offers
a compelling mix of growth, income, and stability. The company’s strong financial
performance, coupled with its strategic market positioning, sets a favorable backdrop
for potential stock appreciation. As healthcare demands continue to grow, Quest 
Diagnostics is well-positioned to capture a significant share, making it a worthy
consideration for any diversified investment portfolio.

Share on:
